146 related articles for article (PubMed ID: 36566257)
21. Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach - a single-center study.
Kuhnle PJ; Israel KF; Menges M
Z Gastroenterol; 2019 May; 57(5):606-610. PubMed ID: 31083749
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG).
Shen J; Zhu X; Du Y; Zhu Y; Yu P; Yang L; Xu Z; Huang L; Zhang Y; Zhang Y; Liu L; Cheng X
Trials; 2021 Oct; 22(1):753. PubMed ID: 34717717
[TBL] [Abstract][Full Text] [Related]
23. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
24. [Effects of robotic and laparoscopic-assisted surgery on lymph node dissection and short-term outcomes in patients with Siewert II adenocarcinoma of esophagogastric junction].
Wang D; Cao S; Tan X; Liu S; Liu X; Niu Z; Chen D; Wang D; Zhang J; Lv L; Li Y; Jiang H; Guo D; Li Y; Li Z; Zhou Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):156-163. PubMed ID: 30799538
[TBL] [Abstract][Full Text] [Related]
25. Novel abdominal approach for dissection of advanced type II/III adenocarcinoma of the esophagogastric junction: a new surgical option.
Hu C; Zhu HT; Xu ZY; Yu JF; Du YA; Huang L; Yu PF; Wang LJ; Cheng XD
J Int Med Res; 2019 Jan; 47(1):398-410. PubMed ID: 30296865
[TBL] [Abstract][Full Text] [Related]
26. Should Splenic Hilar Lymph Nodes be Dissected for Siewert Type II and III Esophagogastric Junction Carcinoma Based on Tumor Diameter?: A Retrospective Database Analysis.
Lv CB; Huang CM; Zheng CH; Li P; Xie JW; Wang JB; Lin JX; Lu J; Chen QY; Cao LL; Lin M; Tu RH
Medicine (Baltimore); 2016 May; 95(21):e3473. PubMed ID: 27227913
[TBL] [Abstract][Full Text] [Related]
27. The Long-Term Outcomes of Surgery Versus Endoscopic Treatment in Patients With Siewert Type II T1M0N0 Adenocarcinoma of the Esophagogastric Junction.
Chen H; Yu X; Yang R; Li S; Zhang G; Si X; Zhou X
Cancer Control; 2022; 29():10732748221143389. PubMed ID: 36523149
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Ryoo BY; Kang YK; Im YH; Kim YJ; Kim BS; Kim TY; Jung SH; Park JH; Baek HJ; Kim YC; Shim YM; Kim CM; Zo JI
Am J Clin Oncol; 1999 Jun; 22(3):253-7. PubMed ID: 10362331
[TBL] [Abstract][Full Text] [Related]
29. Influence of Primary Tumor Resection on Survival of Patients With Metastatic Siewert Type II Adenocarcinoma of the Esophagogastric Junction: A Population-Based, Propensity-Matched Analysis.
Chen J; Jia X; Chen H; Cai J; Chen L
Cancer Control; 2023; 30():10732748231208313. PubMed ID: 37851478
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of the superiority of different TNM staging systems in Siewert III adenocarcinoma of esophagogastric junction].
Lu Y; Xi H; Xie T; Qiu Z; Wang X; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):143-148. PubMed ID: 30799536
[TBL] [Abstract][Full Text] [Related]
31. Comparison between gastric and esophageal classification system among adenocarcinomas of esophagogastric junction according to AJCC 8th edition: a retrospective observational study from two high-volume institutions in China.
Liu K; Feng F; Chen XZ; Zhou XY; Zhang JY; Chen XL; Zhang WH; Yang K; Zhang B; Zhang HW; Zhou ZG; Hu JK
Gastric Cancer; 2019 May; 22(3):506-517. PubMed ID: 30390154
[TBL] [Abstract][Full Text] [Related]
32. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients.
Blank S; Rachakonda S; Keller G; Weichert W; Lordick F; Langer R; Springfeld C; Bruckner T; Becker K; Kumar R; Ott K
BMC Cancer; 2014 Feb; 14():58. PubMed ID: 24490800
[TBL] [Abstract][Full Text] [Related]
33. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
[No Abstract] [Full Text] [Related]
34. Short-term outcomes after laparoscopic versus open transhiatal resection of Siewert type II adenocarcinoma of the esophagogastric junction.
Sugita S; Kinoshita T; Kaito A; Watanabe M; Sunagawa H
Surg Endosc; 2018 Jan; 32(1):383-390. PubMed ID: 28656339
[TBL] [Abstract][Full Text] [Related]
35. Patterns of recurrence in adenocarcinoma of the esophagogastric junction: a retrospective study.
Xu H; Zhang L; Miao J; Liu S; Liu H; Jia T; Zhang Q
World J Surg Oncol; 2020 Jun; 18(1):144. PubMed ID: 32593312
[TBL] [Abstract][Full Text] [Related]
36. [Surgical strategy for adenocarcinoma of esophagogastric junction].
Lu Y; Zhang K; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb; 22(2):107-111. PubMed ID: 30799532
[TBL] [Abstract][Full Text] [Related]
37. Value of splenectomy in patients with Siewert type II adenocarcinoma of the esophagogastric junction.
Goto H; Tokunaga M; Sugisawa N; Tanizawa Y; Bando E; Kawamura T; Niihara M; Tsubosa Y; Terashima M
Gastric Cancer; 2013 Oct; 16(4):590-5. PubMed ID: 23179369
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
Bang YJ; Kim YW; Yang HK; Chung HC; Park YK; Lee KH; Lee KW; Kim YH; Noh SI; Cho JY; Mok YJ; Kim YH; Ji J; Yeh TS; Button P; Sirzén F; Noh SH;
Lancet; 2012 Jan; 379(9813):315-21. PubMed ID: 22226517
[TBL] [Abstract][Full Text] [Related]
39. [Comparison of efficacy between laparoscopic and open proximal gastrectomy with double-tract reconstruction for Siewert type Ⅱ and Ⅲ adenocarcinoma of the esophagogastric junction].
Ma F; Peng LQ; Liu CP; Zhang YL; Wang L; Zhang B; Ma Q; Ji SQ; Chai JH; Tang XC; Zhao EJ; Hua YW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):420-425. PubMed ID: 34000771
[No Abstract] [Full Text] [Related]
40. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
